How Vascular Occlusion Occurs
Vascular occlusion is the most serious complication of hyaluronic acid (HA) dermal fillers. It occurs when filler enters or compresses an artery and interrupts perfusion of the tissue that vessel supplies. Two mechanisms operate: direct intravascular injection, in which material is deposited inside the lumen, and external compression, in which a periarterial bolus narrows or closes the vessel. Both reduce downstream flow and, if unrecognised, lead to ischaemia and necrosis.
The facial arteries most often implicated follow predictable courses. The angular and lateral nasal branches, the dorsal nasal artery, the supratrochlear and supraorbital vessels of the glabella, the superior and inferior labial arteries, and the facial artery in the nasolabial fold are all recognised danger zones. Rich anastomoses mean that filler placed in one territory can travel retrograde and embolise into distant circulations, including the eye.
Retrograde embolisation explains the gravest sequela, sight loss. When injection pressure exceeds arterial pressure, a column of filler can move backward along the ophthalmic arterial system and then flow forward into the central retinal or posterior ciliary arteries. This anatomical continuity is why glabellar and nasal treatment attracts particular caution, and why depth, tissue plane, and injection pressure are treated as central to safety.
Recognising the Early Signs
Early recognition rests on a pattern rather than any single sign. Immediate blanching along a vascular distribution, pain that is disproportionate to the procedure, and a dusky, mottled or livedo-reticularis appearance form the classical picture. Symptoms may begin during injection or over the following hours. Because ischaemia evolves, the clinician re-examines rather than reassures, comparing the treated area against its normal counterpart on the other side.
Several features help distinguish occlusion from expected bruising or oedema after treatment. Delayed capillary refill, coolness to the touch, and a demarcated colour change that follows a vessel rather than the injection site all raise concern. When present, any of the following features warrant urgent reassessment rather than reassurance:
Distinguishing occlusion from a simple haematoma matters because management diverges sharply. Bruising is soft, spreads diffusely, and is not painful on gentle pressure; occlusion follows an arterial territory, is often painful, and progresses over time. When uncertainty remains, the safer interpretation is to treat as occlusion. A short delay in reperfusion narrows the window during which hyaluronidase can restore flow.
- Blanching or a white-grey mottling that appears immediately after injection
- Pain that is severe, increasing, or out of proportion to the technique used
- A dusky, blue-grey, or livedo (reticulated) discolouration of the skin
- Capillary refill delayed beyond two to three seconds in the affected area
- Any visual disturbance, ocular pain, ptosis, or new severe headache
The Immediate Management Algorithm
Management begins the moment occlusion is suspected; certainty is not required to act. The priority is to restore perfusion before ischaemia becomes irreversible. HA fillers carry an advantage here, because hyaluronidase can dissolve the offending material. The response is systematic, and every practitioner injecting HA should be able to initiate it without hesitation and know the point at which to escalate.
A widely taught sequence gives the response structure and helps prevent hesitation under pressure. It is rehearsed in advance so that each step follows the last without the practitioner having to reason from first principles during an emergency. The core steps, adapted to local protocols and the individual case, are as follows:
Hyaluronidase is central, and dosing is generous rather than cautious; repeated high-dose administration guided by clinical response is the accepted approach for cutaneous occlusion. It should be immediately available wherever HA is injected, alongside a written protocol. Practitioners also confirm in advance how they would obtain further supplies and specialist support out of hours, since delay is the principal determinant of outcome.
Because hyaluronidase can rarely provoke hypersensitivity or anaphylaxis, resuscitation equipment and appropriate training belong in the same setting as the treatment. Documentation runs alongside care: time of onset, doses given, and the response observed. The aim throughout is reperfusion and safe escalation, not one decisive intervention. Serial photographs help track progression and inform the team that receives the patient.
- Stop injecting immediately and withdraw the needle or cannula from the tissue
- Inject hyaluronidase generously into and around the affected territory, repeating at intervals until perfusion improves
- Apply warmth and gentle massage to encourage vasodilation and dispersal of the filler
- Consider aspirin per local protocol and reassess capillary refill frequently
- Escalate early, arranging specialist or emergency review if perfusion does not return
The Visual-Loss Emergency
Visual symptoms after facial filler represent a different order of emergency. Sudden vision loss, whether painful or painless, together with diplopia, ptosis, ophthalmoplegia, or a fixed pupil, suggests retinal or ophthalmic arterial occlusion. Skin changes over the forehead, nose, or around the eye may accompany them. The therapeutic window is very short, measured in minutes to a few hours, before retinal ischaemia becomes permanent.
No treatment reliably restores vision once the central retinal artery is fully occluded, which places the emphasis on immediate escalation rather than improvisation. The practitioner stops, does not continue injecting, and arranges emergency transfer to ophthalmology. Measures such as ocular massage, rebreathing, and pressure-lowering agents are described in the literature, but none should delay urgent specialist assessment.
Retrobulbar hyaluronidase has been proposed, yet the evidence for its efficacy is limited and it requires expertise that most injectors do not hold. For that reason, a practical pathway agreed in advance — which unit, by what route, and whom to telephone — matters more than any single manoeuvre. Identifying the nearest emergency ophthalmology service before treating is a basic safeguard, not an optional refinement.
Prevention and Training
Prevention reduces but never removes risk, and stating this plainly matters in training. Sound anatomical knowledge is the foundation: understanding vessel depth, course, and variation lets the injector select planes that avoid arteries. Injecting slowly, in small aliquots, at low pressure, and withdrawing the needle while depositing product all lessen both the chance and the volume of any intravascular deposit.
Technique choices are debated rather than settled. Aspiration before injection is imperfect, and a negative result does not exclude intravascular placement; blunt cannulas may lower risk in some regions but are not immune to it. What matters is that the practitioner understands the trade-offs, works within their competence, and treats each product and site on its own terms rather than following a single rule.
Professional standards frame all of this. UK guidance from the General Medical Council, the General Dental Council, and the Joint Council for Cosmetic Practitioners expects practitioners to work within their competence, keep their skills current, and manage complications they may cause. Preparedness — accessible hyaluronidase, a written emergency protocol, and a rehearsed escalation route — is a marker of responsible practice.
Structured education has a role in building and maintaining these skills. ATDERA develops faculty-led educational programmes for practising clinicians, and a well-designed course should combine applied anatomy, complication drills, and honest discussion of limits. A certificate of attendance or completion records participation and learning; it does not by itself confer independent competence or a licence to perform procedures unsupervised.